nach oben

Esophagus

Erschienen in:

09.01.2017 | Review Article

Radiation-induced heart disease after treatment for esophageal cancer

verfasst von: Keiichi Jingu, Rei Umezawa, Katsuya Fukui

Erschienen in: Esophagus | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Recently, the development of radiotherapy technology and to radiation-induced heart disease in patients with esophageal cancer. Investigations using chemotherapy has improved treatment results for esophageal cancer, and attention has been paidSEER for esophageal cancer showed that the hazard ratio of heart-related death was 1.62–1.96. Herein we review published literature regarding the mechanism of and countermeasures for radiation-induced heart disease and discuss the potential of concurrent chemotherapy, molecular-targeted agents and lifestyle for exacerbating radiation-induced heart disease.

Ariga H, Nemoto K, Miyazaki S, et al. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;75(2):348–56.CrossRefPubMed

Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer—a meta-analysis of the randomized trials. Cancer Treat Rev. 2012;38:599–604.CrossRefPubMed

Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24:4107.CrossRefPubMed

Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21:3431–9.CrossRefPubMed

Ozasa K, Takahashi I, Grant EJ. Radiation-related risks of non-cancer outcomes in the atomic bomb survivors. Ann ICRP. 2016;45(1 Suppl):253–61.CrossRefPubMed

Jingu K, Matsushita H, Takeda K, et al. Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients. Dis Esophagus. 2013;26(5):522–7.CrossRefPubMed

Jingu K, Umezawa R, Matsushita H, et al. Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan. Int J Clin Oncol. 2016;21(2):276–82.CrossRefPubMed

Umezawa R, Jingu K, Matsushita H, et al. Long-term results of chemoradiotherapy for stage II–III thoracic esophageal cancer in a single institution after 2000—with a focus on comparison of three protocols. BMC Cancer. 2015;15:813.CrossRefPubMedPubMedCentral

Nishimura Y, Jingu K, Itasaka S, et al. Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG). Int J Clin Oncol. 2016;21(1):88–94.CrossRefPubMed

10.

Yamada S, Nemoto K, Takai Y, et al. Proposal for standard radiotherapy methods for superficial esophageal cancer: a multicenter retrospective evaluation. J JASTRO. 2000;12:169–76.

11.

Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21(14):2697–702.CrossRefPubMed

12.

Frandsen J, Boothe D, Gaffney DK, et al. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointest Oncol. 2015;6:516–23.PubMedPubMedCentral

13.

Gharzai L, Verma V, Denniston KA, et al. Radiation therapy and cardiac death in long-term survivors of esophageal cancer: an analysis of the surveillance, epidemiology, and end result database. PLoS One. 2016;11(7):e0158916.CrossRefPubMedPubMedCentral

14.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801.CrossRefPubMed

15.

Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27(8):766–73.CrossRefPubMed

16.

Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76:656–65.CrossRefPubMedPubMedCentral

17.

Carmel RJ, Kaplan HS. Mantle irradiation in Hodgkin’s disease. An analysis of technique, tumour eradication, and complications. Cancer. 1976;37:2813–25.CrossRefPubMed

18.

Karram T, Rinkevitch D, Markiewicz W. Poor outcome in radiation-induced constrictive pericarditis. Int J Radiat Oncol Biol Phys. 1993;25(2):329–31.CrossRefPubMed

19.

Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008;70:707–14.CrossRefPubMed

20.

Tamari K, Isohashi F, Akino Y, et al. Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy. Anticancer Res. 2014;34(12):7389–93.PubMed

21.

Fukuda J, Shigematsu N, Takeuchi H, et al. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2013;87(3):487–93.CrossRefPubMed

22.

Nishizawa S, Nakamura T, Shiraishi H, et al. Successful treatment with low dose steroids for recurrent radiation pericarditis after chemoradiotherapy of lower esophageal cancer: a case report. Heart 2010;42:369–374 (Japanese).

23.

Nishimura Y, Hiraoka M, Koike R, et al. Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol. 2012;42(9):807–12.CrossRefPubMed

24.

Gladstone DJ, Flanagan MF, Southworth JB, et al. Radiation-induced cardiomyopathy as a function of radiation beam gating to the cardiac cycle. Phys Med Biol. 2004;49:1475–84.CrossRefPubMed

25.

Weintraub NL, Jones WK, Manka D. Understanding radiation-induced vascular disease. J Am Coll Cardiol. 2010;55(12):1237–9.CrossRefPubMed

26.

Seddon B, Cook A, Gothard L, et al. Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol. 2002;64(1):53–63.CrossRefPubMed

27.

Umezawa R, Takase K, Jingu K, et al. Evaluation of radiation-induced myocardial damage using iodine-123 β-methyl-iodophenyl pentadecanoic acid scintigraphy. J Radiat Res. 2013;54(5):880–9.CrossRefPubMedPubMedCentral

28.

Umezawa R, Takanami K, Kadoya N, et al. Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study. Radiat Oncol. 2015;10(1):96.CrossRefPubMedPubMedCentral

29.

Gyenes G, Rutqvist LE, Liedberg A, Fornander T. Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol. 1998;48(2):185–90.CrossRefPubMed

30.

Ling TC, Slater JM, Nookala P, et al. Analysis of intensity-modulated radiation therapy (IMRT), proton and 3D conformal radiotherapy (3D-CRT) for reducing perioperative cardiopulmonary complications in esophageal cancer patients. Cancers (Basel). 2014;6(4):2356–68.CrossRefPubMedPubMedCentral

31.

Jingu K, Nemoto K, Kaneta T, et al. Temporal change in brain natriuretic Peptide after radiotherapy for thoracic esophageal cancer. Int J Radiat Oncol Biol Phys. 2007;69(5):1417–23.CrossRefPubMed

32.

Palumbo I, Palumbo B, Fravolini ML, et al. Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients: a prospective study. Breast. 2016;25:45–50.CrossRefPubMed

33.

van der Veen SJ, Ghobadi G, de Boer RA, et al. ACE inhibition attenuates radiation-induced cardiopulmonary damage. Radiother Oncol. 2015;114(1):96–103.CrossRefPubMed

34.

Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70:519–30.CrossRefPubMed

35.

Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743–9.CrossRefPubMed

36.

Malanca M, Cimadevilla C, Brochet E, et al. Radiotherapy-induced mitral stenosis: a three-dimensional perspective. J Am Soc Echocardiogr 2010;23:108.e1–2.

37.

Copeland KA, Hosmane VR, Jurkovitz C, et al. Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center. Clin Cardiol. 2013;36(4):217–21.CrossRefPubMed

38.

Baeuml H, Behrends U, Peter RU, et al. Ionizing radiation induces, via generation of reactive oxygen intermediates, intercellular adhesion molecule-1 (ICAM-1) gene transcription and NF kappa B-like binding activity in the ICAM-1 transcriptional regulatory region. Free Radic Res. 1997;27:127–42.CrossRefPubMed

39.

Gyenes G, Fornander T, Carlens P, et al. Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy. Eur J Nucl Med. 1997;24:286–92.PubMed

40.

Küpeli S, Hazirolan T, Varan A, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma. J Clin Oncol. 2010;28(6):1025–30.CrossRefPubMed

41.

Kaplan BM, Miller AJ, Bharati S, et al. Complete AV block following mediastinal radiation therapy: electrocardiographic and pathologic correlation and review of the world literature. Arch Intern Med. 1981;141:676–9.CrossRef

42.

Tötterman KJ, Pesonen E, Siltanen P. Radiation-related chronic heart disease. Chest. 1983;83(6):875–8.CrossRefPubMed

43.

Slama MS, Le Guludec D, Sebag C, et al. Complete atrioventricular block following mediastinal irradiation: a report of six cases. Pacing Clin Electrophysiol. 1991;14(7):1112–8.CrossRefPubMed

44.

Pohjola-Sintonen S, Tötterman KJ, Kupari M. Sick sinus syndrome as a complication of mediastinal radiation therapy. Cancer. 1990;65:2494–6.CrossRefPubMed

45.

Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol. 2007;7(2):61–6.CrossRefPubMed

46.

Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23(30):7685–96.CrossRefPubMed

47.

Lieutaud T, Brain E, Golgran-Toledano D, et al. 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Eur J Cancer 1996; 32a:368–9.

48.

Chirino J, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009;61:223–42.

49.

Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102–11.CrossRefPubMed

50.

Zhang W, Zhao L, Liu J, et al. Cisplatin induces platelet apoptosis through the ERK signaling pathway. Thromb Res. 2012;130(1):81–91.CrossRefPubMed

51.

Saito K, Takeda K, Yoshida K, et al. Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Ann Nucl Med. 2003;17(6):481–8.CrossRefPubMed

52.

Tomonari M, To H, Nishida M, Mishima T, Sasaki H, Kurose H. Mechanism of the cardioprotective effects of docetaxel pre-administration against adriamycin-induced cardiotoxicity. J Pharmacol Sci. 2011;115(3):336–45.CrossRefPubMed

53.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.CrossRefPubMed

54.

Marinko T, Dolenc J, Bilban-Jakopin C. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radiol Oncol. 2014;48(2):105–12.CrossRefPubMedPubMedCentral

55.

Friess H, Fukuda A, Tang WH, et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg. 1999;23:1010–8.CrossRefPubMed

56.

Cellini F, Valentini V. Targeted therapies in combination with radiotherapy in oesophageal and gastroesophageal carcinoma. Curr Med Chem. 2014;21(8):990–1004.CrossRefPubMed

57.

Ikushima H, Takegawa Y, Yasuda H, et al. Radiation complications following breast conserving therapy. Breast Cancer. 1998;5(4):395–400.CrossRefPubMed

58.

Dorth JA, Patel PR, Broadwater G, et al. Incidence and risk factors of significant carotid artery stenosis in asymptomatic survivors of head and neck cancer after radiotherapy. Head Neck. 2014;36(2):215–9.CrossRefPubMed

Titel: Radiation-induced heart disease after treatment for esophageal cancer
verfasst von: Keiichi Jingu
Rei Umezawa
Katsuya Fukui
Publikationsdatum: 09.01.2017
Verlag: Springer Japan
Erschienen in: Esophagus / Ausgabe 3/2017
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI: https://doi.org/10.1007/s10388-017-0569-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Radiation-induced heart disease after treatment for esophageal cancer

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Postoperative delirium after pharyngolaryngectomy with esophagectomy: a role for ramelteon and suvorexant

Mechanisms underlying excessive esophageal acid exposure in patients with gastroesophageal reflux disease

Barrett’s Esophageal Adenocarcinoma with CREST Syndrome

Helicobacter pylori infection status had no influence on upper gastrointestinal symptoms: a cross-sectional analysis of 3,005 Japanese subjects without upper gastrointestinal lesions undergoing medical health checkups

The treatment results of definitive radiotherapy for cervical esophageal cancer: a single-institution experience

Validation study of a health risk appraisal model and endoscopic screening for early esophageal cancer in men in specialized hospitals

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Update Innere Medizin